Unknown

Dataset Information

0

Early assessment of recurrent glioblastoma response to bevacizumab treatment by diffusional kurtosis imaging: a preliminary report.


ABSTRACT: PURPOSE:The purpose of this preliminary study is to apply diffusional kurtosis imaging to assess the early response of recurrent glioblastoma to bevacizumab treatment. METHODS:This prospective cohort study included 10 patients who had been diagnosed with recurrent glioblastoma and scheduled to receive bevacizumab treatment. Diffusional kurtosis images were obtained from all the patients 0-7 days before (pre-bevacizumab) and 28 days after (post-bevacizumab) initiating bevacizumab treatment. The mean, 10th, and 90th percentile values were derived from the histogram of diffusional kurtosis imaging metrics in enhancing and non-enhancing lesions, selected on post-contrast T1-weighted and fluid-attenuated inversion recovery images. Correlations of imaging measures with progression-free survival and overall survival were evaluated using Spearman's rank correlation coefficient. The significance level was set at P?

SUBMITTER: Lee CY 

PROVIDER: S-EPMC6728698 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Early assessment of recurrent glioblastoma response to bevacizumab treatment by diffusional kurtosis imaging: a preliminary report.

Lee Chu-Yu CY   Kalra Amandeep A   Spampinato Maria V MV   Tabesh Ali A   Jensen Jens H JH   Helpern Joseph A JA   de Fatima Falangola Maria M   Van Horn Mark H MH   Giglio Pierre P  

The neuroradiology journal 20190708 5


<h4>Purpose</h4>The purpose of this preliminary study is to apply diffusional kurtosis imaging to assess the early response of recurrent glioblastoma to bevacizumab treatment.<h4>Methods</h4>This prospective cohort study included 10 patients who had been diagnosed with recurrent glioblastoma and scheduled to receive bevacizumab treatment. Diffusional kurtosis images were obtained from all the patients 0-7 days before (pre-bevacizumab) and 28 days after (post-bevacizumab) initiating bevacizumab t  ...[more]

Similar Datasets

| S-EPMC5703480 | biostudies-literature
| S-EPMC8028790 | biostudies-literature
| S-EPMC4378654 | biostudies-other
| S-EPMC6293510 | biostudies-literature
| S-EPMC7600134 | biostudies-literature
| S-EPMC7861404 | biostudies-literature
| S-EPMC6195210 | biostudies-literature
| S-EPMC5559661 | biostudies-literature
| S-EPMC6258297 | biostudies-literature
| S-EPMC3549661 | biostudies-other